Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules (LARA)
Primary Purpose
Thyroid Nodule
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Percutaneous Laser Ablation
Percutaneous Radiofrequency Ablation
Sponsored by
About this trial
This is an interventional treatment trial for Thyroid Nodule focused on measuring Thyroid Nodule, Percutaneous radiofrequency ablation (RFA), Percutaneous laser ablation (LA)
Eligibility Criteria
Inclusion Criteria:
- Solitary thyroid nodule or dominating nodule which is well-identifiable in multinodular goiter.
- Compressive and /or cosmetic symptoms caused by thyroid nodule or increase in nodule volume >20% in 1 year even without symptoms
- A nodule volume ≥ 5 ml
- Solid nodule (uniformly compact or nearly completely solid, with a liquid component not exceeding 30%);
- Two thyroid biopsies resulted negative for malignancy
- Calcitonin levels within normal ranges
Exclusion Criteria:
- Hyperfunctioning lesion as evaluated biochemically and/or by 99mTc scintigraphy
- Pregnancy
Sites / Locations
- Santa Maria Goretti Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
LA Arm
RFA Arm
Arm Description
Percutaneous Laser Ablation
Percutaneous Radiofrequency Ablation
Outcomes
Primary Outcome Measures
Percentage of thyroid nodules with volume reduction at 6 and 12 months after treatment
Differences in the percentage of nodules with greater than 50% base volume reduction at 6 and 12 months
Secondary Outcome Measures
Basal Volume of Thyroid Nodules as Predictive factor of response to treatment
Basal volume in mL of the nodules will be calculated with the ellipsoid formula
Histopathological features of Thyroid Nodules as Predictive factor of response to treatment
% of amount of fibrosis and colloid components evaluated with score-biopsy
Variation in TSH levels after treatment
Variation in TSH value (mUI/ml) before and after LA and RFA
Variation in AbTPO and AbTg levels after treatment
Variation in AbTPO and AbTg levels (UI/ml) before and after LA and RFA
Complications
Differences in the rate of complications and side effects between LA and RFA
Tolerability evaluated by McGill Pain Questionnaire
Tolerability will be evaluated by McGill Pain Questionnaire, Melzack 1975, italian version
Quality of Life
Quality of Life will be evaluated by SF-36 QoL questionnaire after 6 months and 1 year in both arms.
Full Information
NCT ID
NCT02714946
First Posted
February 19, 2016
Last Updated
September 2, 2019
Sponsor
Campus Bio-Medico University
1. Study Identification
Unique Protocol Identification Number
NCT02714946
Brief Title
Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules
Acronym
LARA
Official Title
Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
September 2019 (Anticipated)
Study Completion Date
January 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Campus Bio-Medico University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to prospectively compare percutaneous radiofrequency ablation (RFA) versus percutaneous laser ablation (LA) for the treatment of solid thyroid nodules.
Detailed Description
Nodular thyroid disease is a common clinical problem whose prevalence increases with age and with a more widespread use of thyroid ultrasonography. Although most thyroid nodules are benign and need only periodic monitoring, some may require treatment for associated pressure and/or cosmetic symptoms. Although thyroid surgery is the main therapeutic approach for compressive thyroid nodules, it may be associated with several drawbacks. Long-term levothyroxine suppression treatment in elderly patients with large nodular goiters is unsatisfactory because it is ineffective. Furthermore, it is associated with adverse effects on bones and the cardiovascular system. Nonsurgical, minimally invasive treatment modalities such as percutaneous laser ablation (LA) and radiofrequency ablation (RFA) have been used to treat thyroid nodules. However no studies comparing LA and RFA have been published so far.
Aims of the study
To evaluate whether LA and RFA cause a reduction ≥50% in the volume of thyroid nodules after 6 months and 1 year follow-up
To evaluate whether the features of thyroid nodules as evaluated by thyroid ultrasound, contrast-enhanced ultrasound, power-doppler and core-biopsy influence LA and RFA outcomes
To evaluate changes in thyroid function and thyroid autoimmunity after LA and RFA.
To evaluate differences between LA and RFA in terms of complications, side effects and tolerability.
Patients will be recruited, treated and followed at Santa Maria Goretti Hospital in Latina, Italy, by physicians with expertise in LA and RFA. The scientific coordinator of this study is dr. Silvia Manfrini.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Nodule
Keywords
Thyroid Nodule, Percutaneous radiofrequency ablation (RFA), Percutaneous laser ablation (LA)
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
LA Arm
Arm Type
Active Comparator
Arm Description
Percutaneous Laser Ablation
Arm Title
RFA Arm
Arm Type
Active Comparator
Arm Description
Percutaneous Radiofrequency Ablation
Intervention Type
Device
Intervention Name(s)
Percutaneous Laser Ablation
Intervention Description
Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
Intervention Type
Device
Intervention Name(s)
Percutaneous Radiofrequency Ablation
Intervention Description
Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
Primary Outcome Measure Information:
Title
Percentage of thyroid nodules with volume reduction at 6 and 12 months after treatment
Description
Differences in the percentage of nodules with greater than 50% base volume reduction at 6 and 12 months
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Basal Volume of Thyroid Nodules as Predictive factor of response to treatment
Description
Basal volume in mL of the nodules will be calculated with the ellipsoid formula
Time Frame
12 months
Title
Histopathological features of Thyroid Nodules as Predictive factor of response to treatment
Description
% of amount of fibrosis and colloid components evaluated with score-biopsy
Time Frame
12 months
Title
Variation in TSH levels after treatment
Description
Variation in TSH value (mUI/ml) before and after LA and RFA
Time Frame
12 months
Title
Variation in AbTPO and AbTg levels after treatment
Description
Variation in AbTPO and AbTg levels (UI/ml) before and after LA and RFA
Time Frame
12 months
Title
Complications
Description
Differences in the rate of complications and side effects between LA and RFA
Time Frame
Up to 1 year follow-up
Title
Tolerability evaluated by McGill Pain Questionnaire
Description
Tolerability will be evaluated by McGill Pain Questionnaire, Melzack 1975, italian version
Time Frame
0 and 6 months
Title
Quality of Life
Description
Quality of Life will be evaluated by SF-36 QoL questionnaire after 6 months and 1 year in both arms.
Time Frame
6 months and 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Solitary thyroid nodule or dominating nodule which is well-identifiable in multinodular goiter.
Compressive and /or cosmetic symptoms caused by thyroid nodule or increase in nodule volume >20% in 1 year even without symptoms
A nodule volume ≥ 5 ml
Solid nodule (uniformly compact or nearly completely solid, with a liquid component not exceeding 30%);
Two thyroid biopsies resulted negative for malignancy
Calcitonin levels within normal ranges
Exclusion Criteria:
Hyperfunctioning lesion as evaluated biochemically and/or by 99mTc scintigraphy
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto Cianni
Organizational Affiliation
Santa Maria Goretti Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Santa Maria Goretti Hospital
City
Latina
ZIP/Postal Code
04100
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
20543551
Citation
Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, Vitti P; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest. 2010;33(5 Suppl):51-6.
Results Reference
background
PubMed Identifier
11110927
Citation
Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, Pacella S, Papini E. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology. 2000 Dec;217(3):673-7. doi: 10.1148/radiology.217.3.r00dc09673.
Results Reference
background
PubMed Identifier
21273519
Citation
Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011 Feb;258(2):351-69. doi: 10.1148/radiol.10081634.
Results Reference
background
PubMed Identifier
17381356
Citation
Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, Pacella S, Valle D, Pacella CM. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid. 2007 Mar;17(3):229-35. doi: 10.1089/thy.2006.0204.
Results Reference
background
PubMed Identifier
25387256
Citation
Cesareo R, Pasqualini V, Simeoni C, Sacchi M, Saralli E, Campagna G, Cianni R. Prospective study of effectiveness of ultrasound-guided radiofrequency ablation versus control group in patients affected by benign thyroid nodules. J Clin Endocrinol Metab. 2015 Feb;100(2):460-6. doi: 10.1210/jc.2014-2186. Epub 2014 Nov 11.
Results Reference
background
Learn more about this trial
Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules
We'll reach out to this number within 24 hrs